SCHEMBL15917388

SCHEMBL15917388

Fc1ccc(CNc2ccnc(-c3cccc(C(F)(F)F)c3)n2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 2/20 0.53
CLK4 Q9HAZ1 16/20 0.47
CYP1A2 P05177 13/20 0.47
CYP3A4 P08684 13/20 0.47
CYP2C19 P33261 13/20 0.47
CYP2D6 P10635 12/20 0.47
TSHR P16473 8/20 0.47
LMNA P02545 7/20 0.47
USP2 O75604 6/20 0.47
ALOX15 P16050 6/20 0.47
MAPK1 P28482 5/20 0.47
CYP2C9 P11712 3/20 0.47
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 4/20 0.45
DYRK1A Q13627 5/20 0.43
TP53 P04637 4/20 0.43
GLA P06280 1/20 0.43
HSD17B10 Q99714 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14554917 0.86 CLK4 (0.44) VNN1CLK4CYP1A2CYP3A4CYP2C19
SCHEMBL15918270 0.81 CLK4 (0.62) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL15917854 0.79 CYP1A2 (0.70) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL15918278 0.78 CLK4 (0.54) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL15935057 0.77 CLK4 (0.45) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14554837 0.77 HDAC3 (0.46) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL14486385 0.76 VNN1 (0.47) VNN1CLK4CYP1A2CYP3A4CYP2C19
SCHEMBL15918070 0.75 CYP1A2 (0.51) CLK4CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL11390484 0.75 AURKA (0.47) CYP1A2CYP3A4ALOX15ALDH1A1
SCHEMBL14486039 0.75 CLK4 (0.50) CLK4CYP1A2CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729459-B1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2018-08-22 EP disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer CCNH, CCNA1, MYC VNN1 4438/4885CLK4 4593/4885CYP1A2 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.